PRS6 A COST-EFFECTIVENESS MODEL FOR SMOKING CESSATION THERAPY USING VARENICLINE
S Viswanathan +4 more
openalex +1 more source
The Risk-Benefit Balance of Varenicline for Smoking Cessation
J. Taylor Hays
openalex +1 more source
Genome-Wide Association Study of Varenicline-Aided Smoking Cessation. [PDF]
Coley K +19 more
europepmc +2 more sources
Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats [PDF]
Jade J. Bito‐Onon +4 more
openalex +1 more source
Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading. [PDF]
Johnstone S +11 more
europepmc +1 more source
Varenicline for tobacco dependence: panacea or plight? [PDF]
Jill M. Williams +5 more
openalex +1 more source
Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. [PDF]
Teschke R.
europepmc +1 more source
Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials [PDF]
David P. King +8 more
openalex +1 more source
Recurrent pulmonary embolism and azygos vein thrombosis during varenicline therapy for smoking cessation. [PDF]
Kim S, Carlson B, Chen K, Sabatelli F.
europepmc +1 more source

